Metagenics® Renagen™ DTX: What the Research Shows About Liver, Kidney & Antioxidant Support
CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist
Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience
The Clinical Question
Metagenics® Renagen™ DTX is a multi-ingredient dietary supplement combining N-acetylcysteine (NAC), Cordyceps mycelium extract (Paecilomyces hepiali), Chinese Salvia root (Salvia miltiorrhiza), and B-vitamins. It is marketed for kidney and liver “detoxification support.” This article reviews what the published evidence supports for each key ingredient and what has not been established for the finished Renagen™ DTX product.
Physiologic framing: The liver metabolizes compounds through biotransformation, while the kidneys filter blood and excrete water-soluble waste products. These established physiologic functions are not evidence that a dietary supplement “enhances detoxification” or improves organ function in healthy adults.
Supplement Facts (Per 1-Capsule Serving)
| Ingredient | Amount |
|---|---|
| Vitamin B6 | 10 mg |
| Folate | 680 mcg DFE |
| Vitamin B12 | 125 mcg |
| Cordyceps mycelium extract (Paecilomyces hepiali) | 200 mg |
| Chinese Salvia root (Salvia miltiorrhiza) | 200 mg |
| N-acetylcysteine (NAC) | 200 mg |
Verify other ingredients, allergens, and serving directions on the current product label before use.
What the Evidence Does — and Does Not — Establish
- Established pharmaceutical use: NAC is an established antidote for acetaminophen poisoning at defined doses under clinical supervision; this does not transfer to supplement-dose benefit for healthy adults.
- Large RCT, negative: NAC was not better than placebo for contrast-associated acute kidney injury prevention in the PRESERVE trial (PMID: 29130810).
- Cordyceps: A Cochrane review of Cordyceps sinensis preparations in CKD found largely small, methodologically limited trials and does not establish equivalence to the Paecilomyces hepiali extract in this product.
- Salvia: The 2022 and 2025 systematic reviews reported favorable pooled renal signals for heterogeneous Salvia preparations in established CKD or diabetic kidney disease, but do not establish efficacy of the 200-mg ingredient or finished Renagen™ DTX.
- B-vitamins: These vitamins lower homocysteine, but biomarker improvement has not reliably translated into better CKD clinical outcomes.
- Not established: That Renagen™ DTX improves GFR, treats kidney or liver disease, removes “toxins,” or enhances organ-level detoxification.
Ingredient-by-Ingredient Evidence Review
1. N-Acetylcysteine (NAC) — 200 mg
NAC is a precursor to glutathione and has established pharmaceutical applications at defined clinical doses.
- Acetaminophen poisoning: Established antidote use under clinical supervision; not evidence for routine supplement-dose benefit.
- Contrast-associated AKI: The PRESERVE trial (PMID: 29130810) was a double-blind RCT in 5,177 high-risk angiography patients. Oral NAC was no better than placebo for the primary outcome or contrast-associated AKI.
- Hemodialysis oxidative-stress surrogate: A small double-blind RCT in 40 chronic hemodialysis patients (PMID: 26787572) found that NAC increased total antioxidant capacity relative to placebo. This supports an antioxidant biomarker effect in a specific dialysis population; it does not establish improved kidney function or Renagen™ DTX benefit.
2. Cordyceps Mycelium Extract (Paecilomyces hepiali) — 200 mg
The available systematic-review evidence covers Cordyceps sinensis preparations, not this product’s Paecilomyces hepiali extract. The Cochrane review (PMID: 25519252) found small trials with methodological limitations and could not establish firm clinical benefit. These findings do not establish that this extract or dose improves GFR or provides kidney detoxification benefits.
3. Chinese Salvia Root (Salvia miltiorrhiza) — 200 mg
A 2022 systematic review/meta-analysis (PMID: 35747383) of 32 studies and 2,264 participants reported favorable pooled renal measures in CKD but suboptimal certainty and risk-of-bias ratings. A 2025 systematic review/meta-analysis (Zheng et al., PMID: 41019991) included 21 RCTs and 1,970 participants with diabetic kidney disease and reported favorable pooled changes in renal, proteinuria, inflammatory, and endothelial measures. Both reviews evaluated heterogeneous preparations in established disease and do not establish efficacy of the 200-mg ingredient or finished Renagen™ DTX.
4. B-Vitamins: B6, Folate, B12
B-vitamins lower homocysteine reliably. Renal HOPE-2 (PMID: 18003666) randomized 619 CKD patients to folic acid plus B6 and B12 or placebo for five years. Homocysteine decreased substantially, but the primary cardiovascular outcome was not reduced (29.3% vs. 25.6%, RR 1.19, P=.25). Lowering the biomarker did not reliably translate into better outcomes.
Important Safety Considerations
Manufacturer warning, confirmed on the current label
The current label says: “Do not use if taking blood thinning medications, antihypertensive medications, hypoglycemic medications and insulin, digoxin or nitroglycerin, or before surgery.” Pregnant or breastfeeding individuals and anyone taking medication are directed to consult a healthcare practitioner.
Evidence calibration: This is a manufacturer warning. The strength of independent clinical interaction evidence varies by ingredient and medication; the warning should not be read as proof of a uniformly established clinical interaction for every pairing. Do not use this product with any listed medication or around surgery without prescriber or pharmacist review.
Who May Consider Renagen™ DTX?
- Healthy adults in clinician-supervised integrative protocols where a practitioner has reviewed the full medication list and identified a specific rationale.
- Not appropriate for self-directed use by: Individuals taking any medication listed in the current manufacturer warning; those with CKD, liver disease, or abnormal organ-function tests; or anyone seeking to self-manage kidney or liver concerns.
Pharmacist’s Note
As a PharmD, I distinguish individual-ingredient evidence from evidence for the finished Renagen™ DTX product. NAC has established pharmaceutical use for acetaminophen poisoning, but PRESERVE did not support NAC for contrast-associated AKI. A small dialysis RCT supports an antioxidant biomarker effect, not improved kidney function. Salvia reviews report favorable pooled renal signals, but preparations, doses, and populations differ from this product. The Cordyceps review involves a different species and low-certainty evidence. B-vitamins lower homocysteine, while Renal HOPE-2 demonstrates that biomarker improvement did not translate into a better primary cardiovascular outcome. I do not present Renagen™ DTX as a kidney or liver detoxification product and recommend pharmacist or physician review before use.
Frequently Asked Questions
Q: Does Renagen™ DTX detoxify my kidneys?
A: There is no established clinical evidence that the finished product enhances kidney filtration or detoxification in healthy adults. Kidney concerns require medical evaluation.
Q: Does NAC protect the kidneys during CT scans?
A: The large PRESERVE trial found oral NAC was no better than placebo for preventing contrast-associated AKI.
Q: Can I take this if I have kidney disease?
A: Do not self-direct use in kidney disease. Consult your nephrologist.
Q: I take warfarin. Is this safe?
A: The current manufacturer label says not to use Renagen™ DTX with blood-thinning medications. The independent evidence for individual Salvia–warfarin or Salvia–antiplatelet interactions varies and is not used here to claim a uniformly established interaction. Do not use this product without physician and pharmacist review.
Related Clinical Insights Articles
Selected Key References
- MIXED / NEGATIVE RCT Weisbord SD, et al. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. N Engl J Med. 2018;378:603–614. PMID: 29130810. Large RCT (n=5,177); NAC did not prevent contrast-associated AKI.
- HUMAN RCT — SURROGATE OUTCOME PMID: 26787572. Double-blind RCT in 40 chronic hemodialysis patients; NAC increased total antioxidant capacity relative to placebo. This does not establish kidney-function benefit.
- SYSTEMATIC REVIEW Zhang HW, et al. Cordyceps sinensis for treating chronic kidney disease. Cochrane Database Syst Rev. 2014. PMID: 25519252. Indirect, low-certainty evidence with species mismatch.
- SYSTEMATIC REVIEW / META-ANALYSIS Zhang W, et al. Efficacy and Safety of Salvia miltiorrhiza for Treating Chronic Kidney Diseases. 2022. PMID: 35747383. Favorable pooled signals with suboptimal certainty.
- SYSTEMATIC REVIEW / META-ANALYSIS — DIABETIC KIDNEY DISEASE Zheng S, et al. Effects and safety of Salvia miltiorrhiza on the improvement of renal function, inflammatory factors, and vascular endothelium in patients with diabetic kidney disease: a meta-analysis and systematic review. Front Pharmacol. 2025. PMID: 41019991. Twenty-one RCTs and 1,970 participants; favorable pooled findings for heterogeneous preparations in established disease, not Renagen™ DTX evidence.
- HUMAN RCT — BIOMARKER/OUTCOME DISSOCIATION Renal HOPE-2, PMID: 18003666. RCT (n=619) of folic acid plus B6/B12 versus placebo in CKD; homocysteine decreased, but the primary cardiovascular outcome did not improve (29.3% vs. 25.6%, RR 1.19, P=.25).
FDA Disclaimer
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The information provided is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
Reviewed by: Dai Tran, PharmD, MBA, B.S. View full bio →
CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist
Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience
Khang Pharmacy | 2451 S King Rd., Ste A1, San Jose, CA 95122 | (408) 622-8068 | www.khangpharmacy.com
